Know Cancer

forgot password

A Phase II Study of Weekly ABRAXANE® (Nab-paclitaxel) for Patients With Advanced NSCLC With EGFR Mutations Following Front-line Therapy With EGFR Tyrosine Kinase Inhibitors

Phase 2
18 Years
Open (Enrolling)
Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer

Thank you

Trial Information

A Phase II Study of Weekly ABRAXANE® (Nab-paclitaxel) for Patients With Advanced NSCLC With EGFR Mutations Following Front-line Therapy With EGFR Tyrosine Kinase Inhibitors


I. To evaluate the overall response rate of weekly nab-paclitaxel (paclitaxel
albumin-stabilized nanoparticle formulation) in patients with advanced non-small cell lung
cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations following front-line
therapy with EGFR tyrosine kinase inhibitors (TKI).


I. To evaluate the safety profile of weekly nab-paclitaxel in patients with advanced NSCLC
with EGFR mutations following front-line therapy with an EGFR TKI.

II. To evaluate the time-to-progression and overall survival.


Patients receive paclitaxel albumin-stabilized nanoparticle formulation intravenously (IV)
over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease
progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 4 weeks and then every 3
months thereafter.

Inclusion Criteria:

- Pathologically confirmed non-small cell lung cancer with documented EGFR mutation in
tumor deoxyribonucleic acid (DNA)

- At least one site of measurable disease by Response Evaluation Criteria in Solid
Tumors (RECIST)

- Progressive disease with radiographic evidence of disease progression per
investigator assessment during therapy with an EGFR tyrosine kinase inhibitor in the
metastatic setting; patients may continue EGFR inhibitor therapy throughout the
screening period until the day prior to nab-paclitaxel treatment initiation

- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 at the time of
informed consent

- Platelet count >= 100,000/UL

- Absolute neutrophil count >= 1,500/UL

- Hemoglobin >= 9 g/dL

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = < 2.5 times
upper limit of normal

- Alkaline phosphatase =< 2.5 times upper limit of normal, unless bone metastasis is
present in the absence of liver metastasis

- Bilirubin =< 1.5mg/dL

- Creatinine =< 1.5mg/dL

- Women of child-bearing potential (WOCP) and sexually active men must agree to use
adequate contraception (hormonal or barrier method of birth control or abstinence)
prior to study entry, during treatment and for three months after completing

- Negative serum or urine beta-human chorionic gonadotropin (hCG) pregnancy test at
screening for patients of childbearing potential

- Life expectancy of >= 12 weeks

- Signed and dated informed consent document indicating that the patient has been
informed of all the pertinent aspects of the trial prior to enrollment

Exclusion Criteria:

- Prior conventional cytotoxic chemotherapy for metastatic or recurrent disease; prior
adjuvant, neoadjuvant or chemoradiotherapy for NSCLC is permitted, provided at least
6 months elapsed prior to documented metastatic recurrence

- Patient is < 5 years free of another primary malignancy, except: a) if the other
malignancy is basal cell carcinoma or cervical carcinoma in situ or b) if the other
primary malignancy is not considered clinically significant and is requiring no
active intervention

- Progressive or symptomatic central nervous system (CNS) metastases; patients with
known brain metastasis must have stable disease following treatment with surgery,
radiation or both; in addition, they must be off corticosteroids

- Radiotherapy within 7 days of study treatment

- Peripheral neuropathy grade 2 or greater

- Grade III/IV congestive heart failure, as defined by New York Heart Association
(NYHA) criteria, or myocardial infarction within 6 months

- Any serious or uncontrolled concomitant disorder that, in the opinion of the
investigator, would compromise the patient's ability to complete the study

- Patient has known chronic liver disease, e.g. diagnosis of chronic active hepatitis
or cirrhosis

- Major surgery within 21 days of study treatment; minor surgery within 2 weeks of
study treatment; placement of vascular access device and biopsies allowed and is not
considered major or minor surgery

- Patient with any significant history of non-compliance to medical regimens or with
inability to grant reliable informed consent

- Pregnant or breast feeding females

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall response rate (complete and partial response) defined by RECIST 1.1 criteria

Outcome Description:

The response rate as the proportion and 95% confidence interval of patients who achieved a complete response or partial response will be calculated.

Outcome Time Frame:

Assessed up to 2 years

Safety Issue:


Principal Investigator

Christina Baik

Investigator Role:

Principal Investigator

Investigator Affiliation:

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium


United States: Federal Government

Study ID:




Start Date:

November 2012

Completion Date:

Related Keywords:

  • Recurrent Non-Small Cell Lung Cancer
  • Stage IV Non-Small Cell Lung Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms



Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumSeattle, Washington  98109